Utama › Tumor Wilms › Wilayah Columbia
Kajian klinikal Tumor Wilms di Wilayah Columbia
7 kajian untuk Tumor Wilms sedang mencari peserta di lokasi di Wilayah Columbia.
Bandar di Wilayah Columbia
Teks kajian rasmi (Bahasa Inggeris)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 2
Umur 12 hingga 39 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT04616560Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 2
Sehingga umur 30 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04322318Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
- Children's National Hospital, Washington D.C.
- Childrens National Hospital, Washington D.C.
Mengambil pesertaFasa 1
Umur 1 hingga 23 · Semua jantina · Dikemas kini 13 Ogo 2026 · NCT07172958Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 19 Mei 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Children's National Hospital (Data Collection Only), Washington D.C.
Mengambil pesertaFasa 2
12 Months · Semua jantina · Dikemas kini 6 Mei 2026 · NCT05985161A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's National Medical Center, Washington D.C.
Mengambil pesertaFasa 2
18 Months – 40 Years · Semua jantina · Dikemas kini 12 Ogo 2025 · NCT05135975Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.